Nasopharyngeal carcinoma
MONDO:0015459A carcinoma arising from the nasopharyngeal epithelium. It includes the following types: keratinizing squamous cell carcinoma, nonkeratinizing carcinoma (differentiated and undifferentiated), basaloid squamous cell carcinoma, and papillary adenocarcinoma.
Also known as: cancer of nasopharynx, cancer of the nasopharynx, malignant nasopharyngeal tumor, malignant nasopharyngeal tumour, malignant neoplasm of anterior wall of nasopharynx, malignant neoplasm of lateral wall of nasopharynx, malignant neoplasm of nasopharyngeal wall, malignant neoplasm of nasopharynx
3164 clinical trials for this condition and its sub-types, 211 tagged with Nasopharyngeal carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Nasopharyngeal carcinoma
-
Carcinoma in situ of nasopharynx 1 trial
-
New cancer drug PRO1160 tested in advanced cancers – trial ends early
Disease control Stopped earlyThis study tested a drug called PRO1160 in people with advanced kidney cancer, nasopharyngeal cancer, or non-Hodgkin lymphoma. The goal was to find a safe dose and see if the drug shrinks tumors. The trial was stopped early, so results are limited.
Phase 1/2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Experimental cancer drug TAK-500 tested in 61 patients – study halted early
Disease control Stopped earlyThis early-phase trial tested an experimental drug called TAK-500, alone or with the immunotherapy pembrolizumab, in 61 adults with advanced solid tumors like pancreatic, liver, and lung cancer. The main goals were to check safety and see if the drug could shrink tumors. The stud…
Phase 1/2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Cancer combo trial halted before full results
Disease control Stopped earlyThis early-stage trial tested a combination of two drugs, APG-1387 and toripalimab, in 40 people with advanced solid tumors including colorectal, nasopharyngeal, and lung cancers. The goal was to find a safe dose and see if the combination could control the disease. However, the …
Phase 1/2 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Experimental cancer drug trial ends early
Disease control Stopped earlyThis early-stage study tested an experimental drug called INCB099318 in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and how the body processes it. The study was terminated early, so results are…
Phase 1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Cancer drug combo study halted early – only 15 patients enrolled
Disease control Stopped earlyThis study looked at whether adding the immunotherapy drug nivolumab to standard chemotherapy could help people with nasopharyngeal cancer that has returned or spread. The trial was planned for many participants but was stopped early, so only 15 people took part. Because of the e…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC